Harry Zhabilov's Contact Details

Harry Zhabilov's Company Details

Enzolytics Inc

College Station, Texas, United States • 4 Employees
Research

Enzolytics, Inc. is a Texas based biotech company committed to the commercialization of its proprietary proteins and monoclonal antibodies for the treatment of debilitating infectious diseases. The Company is advancing multiple therapeutics targeting numerous infectious diseases. One patented and clinically tested compound, ITV-1 (Immune Therapeutic Vaccine-1), is a suspension of Inactivated Pepsin Fraction (IPF), which studies have shown is effective in treating HIV/AIDS. IPF is the active component of ITV-1 and is a purified extract of porcine pepsin. ITV-1 has also been shown to modulate the immune system.The Company has also pioneered a proprietary method for creating human cell lines that produce fully human monoclonal antibodies directed against many infectious diseases. One antibody (designated as CLONE 3) has been demonstrated in tests in 5 international labs to fully neutralize over 95% of all strains and viral subtypes of HIV-1 against which it has been tested. This proprietary methodology for producing fully human monoclonal antibodies is currently being employed to produce monoclonal antibody therapeutics for numerous additional infectious diseases, including the Coronavirus (SARS-CoV-2), HTLV-1, Ebola, Influenza A and B, H1N1 influenza, H10N3, Respiratory syncytial virus (RSV), Small-Pox, Tetanus, Diphtheria, Rabies, Herpes zoster, Varicella zoster, Herpes HSV 1/2, Anthrax, Elephant endotheliotropic herpesviruses, Feline Leukemia Virus, Equine Infectious Anemia Virus, and Koala retrovirus.The Company has announced a coherent protocol that it intends to execute to meet the Company's objective of producing a therapeutic cure for targeted viruses as well as a planned protocol to address existing and future pandemics. This protocol has been defined as a result of the Company's collaboration with Intel Corporation in the field of applying computer analysis (Artificial Intelligence – A.I.) to accelerate health care discoveries and development.